Analysis of the mechanism of action of the IDH2 inhibitor enasidenib

Enasidenib is a highly specific IDH2 inhibitor whose research and development background is based on in-depth research on the molecular mechanism of leukemia. Acute myeloid leukemia (AML) is a complex hematological malignant disease, and some patients have IDH2 gene mutations. The IDH2 gene encodes isocitrate dehydrogenase 2, a mitochondrial metabolic enzyme involved in cellular energy metabolism and differentiation. When the IDH2 gene is mutated, the function of the enzyme changes, switching from a normal metabolite to producing an abnormal metabolite, 2-hydroxyglutarate (2-HG).

2-HG is considered a carcinogenic metabolite. It accumulates in large amounts in cells and inhibits a variety of key epigenetic enzymes and differentiation-related enzymes, leading to stasis of hematopoietic stem cell differentiation. In other words, leukemia cells expand indefinitely because they cannot differentiate and mature, eventually forming AML. Traditional chemotherapy can only suppress the disease through non-specific killing of rapidly dividing cells, but has no direct intervention effect on the mechanism driven by this metabolic abnormality. Therefore, the development of drugs targeting IDH2 mutations has become the focus of precision treatment.

Ensidipine blocks the production of abnormal 2-HG from the source by selectively inhibiting the activity of mutantIDH2 enzyme. When the level of 2-HG decreases, the inhibited differentiation pathway is gradually restored, and leukemia cells can re-enter the differentiation process and gradually transform into mature functional blood cells. This mechanism is different from the traditional "killing" idea and is closer to "correcting" abnormalities, so it is called a differentiated treatment model. Similar to previous reliance on all-trans retinoic acid (ATRA) for the treatment of acute promyelocytic leukemia, ensidipine provides a specialized molecular correction strategy for IDH2-mutated AML.

The biggest advantage of this mechanism of action is that it can achieve remission without relying on large doses of cytotoxic drugs, sparing patients from severe chemotherapy-related side effects. Multiple overseas studies have shown that after treatment with ensidipine, the hematological indicators and bone marrow conditions of some patients gradually improved, especially in the relapsed or refractory AML population, showing considerable remission rates and survival benefits.

Reference materials:https://www.idhifa.com/